There’s been no short-age of white-collar prosecutions gone awry in recent years. But that’s probably not much consolation for federal prosecutors in Boston, whose criminal cases against Stryker Corporation and four former company officials abruptly imploded this winter.
According to prosecutors, the defendants had encouraged surgeons to use Stryker medical devices that encourage bone growth in combination with a bone filler called Calstrux — a combination that had never been formally tested in humans or approved by the Food and Drug Administration. Prior to the indictment, the government had struck plea deals with company sales representatives, including several who were set to testify against the Stryker defendants at trial.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
